Mechanisms of Action of Paradoxical Responses to Zolpidem: A Multimodal Study

Conditions

Neurotypical volunteers (representing the general population), Patients with acquired partial/total vision impairments, Patients with Disorders of Consciousness (DoC)

Brief summary

DoC patients: Consciousness level (Coma Recovery Scale-Revised – CRS-R); Neural complexity (high density electroencephalography – hdEEG); Phenomenological experiences (Free recall/interview, if the patient recovers functional communication after IMP/placebo administration), Neurotypical volunteers: Alertness/sleepiness level (Karolinska Sleepiness Scale – KSS); Cognitive performance (Standardised neuropsychological tests); Neural complexity (high density electroencephalography – hdEEG); Phenomenological experiences (Free recall/interview), Patients with vision impairments: Alertness/sleepiness level (Karolinska Sleepiness Scale – KSS); Cognitive performance (Standardised neuropsychological tests); Neural complexity (high density electroencephalography – hdEEG); Phenomenological experiences (Free recall/interview); Visual functions (ophthalmological testing by a neuro-ophthalmologist)

Related papers

No related papers found yet.

Interventions

DRUGMANNITOL

DRUGZolpidem Viatris 10 mg comprimés pelliculés

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
DoC patients: Consciousness level (Coma Recovery Scale-Revised – CRS-R); Neural complexity (high density electroencephalography – hdEEG); Phenomenological experiences (Free recall/interview, if the patient recovers functional communication after IMP/placebo administration), Neurotypical volunteers: Alertness/sleepiness level (Karolinska Sleepiness Scale – KSS); Cognitive performance (Standardised neuropsychological tests); Neural complexity (high density electroencephalography – hdEEG); Phenomenological experiences (Free recall/interview), Patients with vision impairments: Alertness/sleepiness level (Karolinska Sleepiness Scale – KSS); Cognitive performance (Standardised neuropsychological tests); Neural complexity (high density electroencephalography – hdEEG); Phenomenological experiences (Free recall/interview); Visual functions (ophthalmological testing by a neuro-ophthalmologist)	—

Measure

Time frame

DoC patients: Consciousness level (Coma Recovery Scale-Revised – CRS-R); Neural complexity (high density electroencephalography – hdEEG); Phenomenological experiences (Free recall/interview, if the patient recovers functional communication after IMP/placebo administration), Neurotypical volunteers: Alertness/sleepiness level (Karolinska Sleepiness Scale – KSS); Cognitive performance (Standardised neuropsychological tests); Neural complexity (high density electroencephalography – hdEEG); Phenomenological experiences (Free recall/interview), Patients with vision impairments: Alertness/sleepiness level (Karolinska Sleepiness Scale – KSS); Cognitive performance (Standardised neuropsychological tests); Neural complexity (high density electroencephalography – hdEEG); Phenomenological experiences (Free recall/interview); Visual functions (ophthalmological testing by a neuro-ophthalmologist)

—

Countries

Belgium

Outcome results

None listed